Current understanding of the effect of sodium-glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus.
作者信息
Watada Hirotaka
机构信息
Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421 Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
出版信息
Diabetol Int. 2020 Jun 8;11(3):242-244. doi: 10.1007/s13340-020-00443-9. eCollection 2020 Jul.
Abstract
摘要
相似文献
1
Current understanding of the effect of sodium-glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus.目前对钠-葡萄糖协同转运蛋白2抑制剂在亚洲糖尿病患者中作用的认识。
Diabetol Int. 2020 Jun 8;11(3):242-244. doi: 10.1007/s13340-020-00443-9. eCollection 2020 Jul.
2
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.钠-葡萄糖共转运蛋白抑制剂治疗 1 型糖尿病。
Clin Drug Investig. 2020 Nov;40(11):991-1000. doi: 10.1007/s40261-020-00949-9.
3
Effects of sodium glucose co-transporter 2 inhibitors on the kidney.钠-葡萄糖协同转运蛋白2抑制剂对肾脏的影响。
Diab Vasc Dis Res. 2018 Sep;15(5):375-386. doi: 10.1177/1479164118783756. Epub 2018 Jul 2.
4
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.心力衰竭风险分层与钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的疗效。
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
5
Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病心力衰竭患者：当前证据与未来方向。
Diabet Med. 2019 Dec;36(12):1550-1561. doi: 10.1111/dme.14140. Epub 2019 Oct 10.
6
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.钠-葡萄糖共转运蛋白 2 抑制剂用于预防 2 型糖尿病患者的心血管事件：系统评价和荟萃分析。
J Am Heart Assoc. 2020 Feb 4;9(3):e014908. doi: 10.1161/JAHA.119.014908. Epub 2020 Jan 29.
7
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.抗糖尿病药物对2型糖尿病大血管并发症发生率和死亡率的影响：钠-葡萄糖协同转运蛋白2抑制剂的新视角
Ann Med. 2017 Feb;49(1):51-62. doi: 10.1080/07853890.2016.1226514. Epub 2016 Sep 22.
8
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.钠-葡萄糖协同转运蛋白2抑制剂联合二肽基肽酶-4抑制剂治疗2型糖尿病：当前临床证据及理论依据综述
Drug Des Devel Ther. 2017 Mar 21;11:923-937. doi: 10.2147/DDDT.S121899. eCollection 2017.
9
[Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria].2型糖尿病合并药物性糖尿患者的尿路感染
Ter Arkh. 2020 Dec 26;92(11):106-109. doi: 10.26442/00403660.2020.11.000581.
10
An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium-glucose cotransporter-2 inhibitors: A case report.钠-葡萄糖共转运蛋白 2 抑制剂引起的非典型高渗高血糖状态伴糖尿病酮症酸中毒：一例报告。
J Formos Med Assoc. 2020 Aug;119(8):1325-1328. doi: 10.1016/j.jfma.2019.11.015. Epub 2019 Dec 5.
引用本文的文献
1
Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).依帕列净在日本2型糖尿病合并肾功能不全患者中的安全性和有效性：一项上市后3年监测研究（STELLA-LONG TERM）的亚组分析
Diabetol Int. 2020 Nov 23;12(2):181-196. doi: 10.1007/s13340-020-00470-6. eCollection 2021 Apr.
2
Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.依帕列净在老年与非老年日本2型糖尿病患者中的安全性和有效性：STELLA-LONG TERM亚组分析
Diabetes Ther. 2021 May;12(5):1359-1378. doi: 10.1007/s13300-021-01042-w. Epub 2021 Mar 17.
本文引用的文献
1
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.达格列净与 2 型糖尿病患者的心血管结局
N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
2
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
3
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME.恩格列净与亚洲2型糖尿病合并已确诊心血管疾病患者的心血管结局——EMPA-REG OUTCOME研究结果
Circ J. 2017 Jan 25;81(2):227-234. doi: 10.1253/circj.CJ-16-1148. Epub 2016 Dec 23.
4
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
5
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Zotero 插件